Arcutis Biotherapeutics (ARQT) Accumulated Expenses (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Accumulated Expenses of $137.0 million for Q1 2026, up 108.27% year-over-year from $65.8 million in Q1 2025, and up 17.75% quarter-over-quarter from $116.3 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Accumulated Expenses (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $137.0 million for Q1 2026.
- In Q1 2026, Accumulated Expenses rose 108.27% year-over-year to $137.0 million; the TTM figure through Mar 2026 stood at $137.0 million (up 108.27% YoY), while the FY2025 annual figure was $116.3 million, up 74.14% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $137.0 million, up from $116.3 million in the prior quarter.
- The five-year high for Accumulated Expenses was $137.0 million in Q1 2026, with the low at $18.5 million in Q2 2022.
- The 5-year median for Accumulated Expenses is $33.9 million (2023), against an average of $52.6 million.
- The sharpest annual moves came in 2023 and 2024: Accumulated Expenses increased 0.71% in 2023, then soared 126.67% in 2024.
- Arcutis Biotherapeutics' Accumulated Expenses stood at $28.3 million in 2022, then grew by 19.84% to $33.9 million in 2023, then jumped by 96.79% to $66.8 million in 2024, then soared by 74.14% to $116.3 million in 2025, then increased by 17.75% to $137.0 million in 2026.
- Business Quant data shows ARQT's Accumulated Expenses at $137.0 million in Q1 2026, $116.3 million in Q4 2025, and $93.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 146.79 Mn |
| Mar 31, 2026 | 136.96 Mn |
| Dec 31, 2025 | 116.31 Mn |
| Sep 30, 2025 | 92.98 Mn |
| Jun 30, 2025 | 87.85 Mn |
| Mar 31, 2025 | 65.76 Mn |
| Dec 31, 2024 | 66.79 Mn |
| Sep 30, 2024 | 52.79 Mn |
| Jun 30, 2024 | 42.63 Mn |
| Mar 31, 2024 | 33.58 Mn |
| Dec 31, 2023 | 33.94 Mn |
| Sep 30, 2023 | 28.00 Mn |
| Jun 30, 2023 | 18.81 Mn |
| Mar 31, 2023 | 23.86 Mn |
| Dec 31, 2022 | 28.32 Mn |
| Sep 30, 2022 | 27.80 Mn |
| Jun 30, 2022 | 18.46 Mn |
| Mar 31, 2022 | 19.99 Mn |
| Dec 31, 2021 | 25.54 Mn |
| Sep 30, 2021 | 13.88 Mn |